VaxNewMo: bioconjugating antibacterial vaccines

VaxNewMo’s platform could yield new, less costly glycoconjugate vaccines

VaxNewMo is developing a bioengineered platform that could yield inexpensive glyconjugate vaccines that prevent bacterial infections, including those not yet covered by existing vaccines.

Traditional chemical glycoconjugation is laborious and expensive, as it typically involves separate GMP processes to produce and purify the polysaccharide and the carrier protein, followed by a series of chemical reactions to link the two parts.

Compounding the problem is the antigenic diversity of pathogens’

Read the full 683 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE